Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

Clinical Pharmacokinetics
Yanhua GaoMichael Barras

Abstract

The objective of this article is to investigate the influence of blood sampling times on tobramycin exposure estimation and clinical decisions and to determine the best sampling times for two estimation methods used for therapeutic drug monitoring. Adult patients with cystic fibrosis, treated with once-daily intravenous tobramycin, were intensively sampled over one 24-h dosing interval to determine true exposure (AUC0-24). The AUC0-24s were then estimated using both log-linear regression and Bayesian forecasting methods for 21 different sampling time combinations. These were compared to true exposure using relative prediction errors. The differences in subsequent dose recommendations were calculated. Twelve patients, with a median (range) age of 25 years (18-36) and weight of 66.5 kg (50.6-76.4) contributed 96 tobramycin concentrations. Five hundred and eighty-eight estimated AUC0-24s were compared to 12 measured true AUC0-24 values. Median relative prediction errors ranged from - 34.7 to 45.5% for the log-linear regression method and from - 14.46 to 11.23% for the Bayesian forecasting method across the 21 sampling combinations. The most unbiased exposure estimation was provided from concentrations sampled at 100/640 min after ...Continue Reading

References

Oct 1, 1984·The American Journal of Medicine·R D MooreP S Lietman
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner, S L Beal
Feb 1, 1997·British Journal of Clinical Pharmacology·S B DuffullE J Begg
Feb 27, 1999·Antimicrobial Agents and Chemotherapy·A D KashubaJ S Bertino
May 1, 1999·Antimicrobial Agents and Chemotherapy·M P Mingeot-Leclercq, P M Tulkens
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·P M BeringerB J Shapiro
Aug 2, 2001·Internal Medicine Journal·J A Phillips, S C Bell
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Jun 21, 2005·Diagnostic Microbiology and Infectious Disease·Johan W MoutonAlphonsus M Horrevorts
Jul 11, 2006·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Kingsley P CoulthardJohn Turnidge
Feb 19, 2011·American Journal of Respiratory and Critical Care Medicine·Malena Cohen-CymberknohEitan Kerem
May 6, 2011·Journal of Clinical Pharmacology·Stefanie HennigMats O Karlsson
Feb 20, 2013·Clinical Pharmacokinetics·Stefanie HennigAlison H Thomson
Apr 29, 2014·The Lancet Infectious Diseases·Jason A RobertsUNKNOWN International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the Europe
Jan 30, 2015·International Journal of Antimicrobial Agents·Sebastian G WichaCharlotte Kloft
Mar 24, 2016·Antimicrobial Agents and Chemotherapy·Celeste BloomfieldStefanie Hennig
Aug 31, 2016·Antimicrobial Agents and Chemotherapy·Michael A BarrasRoss L G Norris
Dec 22, 2017·Antimicrobial Agents and Chemotherapy·Yanhua GaoStefanie Hennig

❮ Previous
Next ❯

Citations

Dec 1, 2020·Deutsche medizinische Wochenschrift·Christina KönigSebastian G Wicha
Mar 25, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Anne-Grete MärtsonJan-Willem C Alffenaar
Feb 11, 2021·Clinical Pharmacology and Therapeutics·Sebastian G WichaUNKNOWN International Society of Anti-Infective Pharmacology (ISAP), the PK/PD study group of the European Society of Clinical Micro
Aug 12, 2021·The Journal of Antimicrobial Chemotherapy·Min DongLisa L Hunter
Sep 25, 2021·British Journal of Clinical Pharmacology·Ranita KirubakaranSophie L Stocker
Oct 28, 2021·British Journal of Clinical Pharmacology·Álvaro Corral AlaejosJonás Samuel Pérez-Blanco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.